Axsome Therapeutics Inc. (AXSM)

NasdaqGM: AXSM · Precio en tiempo real · USD

215.69

-0.58 (-0.27%)

Al cierre: Aug 19, 2026, 8:00 PM

220.00

+0.82%

Fuera de horario: 6:12 PM

-0.27% (1D)

No hay datos disponibles

Precio de compra	170.52
Capitalización de mercado	11.43B
Ingresos (TTM)	776.57M
Beneficio neto (TTM)	-191.64M
Beta	0.73
EPS (TTM)	-3.75
Ratio PER (TTM)	n/a
Adelante PE	43.35
P/B (TTM)	136.97
P/S (TTM)	14.72
Earnings Date	Nov 2, 2026

Precio de venta	259.2
Volumen	469,148
Volumen medio (20D)	873,851
Abierto	215.93
Anterior Cerrar	216.27
Rango del día	214.39 - 220.00
Rango de 52 semanas	111.55 - 260.19
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (so...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Nov 19, 2015

Empleados 1,346

Bolsa de Valores NasdaqGM

Símbolo bursátil AXSM

Sitio web https://www.axsome.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Axsome Therapeutics fueron 638.5M, un aumento de 65.55% en comparación con 385.69M del año anterior. Las ganancias fueron -183.17M, una disminución de -36.22%.

Estados financieros

Sorpresa de resultados

Axsome Therapeutics ha publicado sus resultados trimestrales en Aug 10, 2026:

Ingresos de $191.2M falla las estimaciones por $0, con 57.42% Crecimiento interanual.

EPS de -0.99 falla las estimaciones por -0.21, con -2.06% Disminución interanual.

Próxima publicación de resultados

Está previsto que Axsome Therapeutics Inc. publique sus resultados el Nov 2, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Zacks

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

1 semana hace · Simply Wall St.

Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now?

Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net loss of US$51.31 million. Earnin...

1 semana hace · Simply Wall St.

Does Axsome Therapeutics (AXSM) Look Fairly Valued At This Price?

Axsome Therapeutics has delivered a very large 5 year return while the current valuation checks point to a stock that now looks closer to fairly priced than clearly cheap. The market has rewarded the ...